Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity
Authors' conclusion
GLP-1RAs may offer greater MACE reductions in Asian compared with White individuals.
Study context
- Population
- Randomized placebo-controlled cardiovascular outcome trials (CVOTs) of GLP-1 RAs in populations with or without T2D and/or overweight or obesity; PubMed and ClinicalTrials.gov, 1 January 2015 to 1 November 20248 trials
- Participants
- 5,909 vs 55,855
- Comparison
- GLP-1 RA vs placebo: Major adverse cardiovascular events (MACE) in Asian vs White individuals
- Asiann = 5,909
- Whiten = 55,855reference
- Outcome
- Ethnicity-specific hazard ratios (HRs) for MACE
Methodological detailsrandom-effects, PRISMA, risk of bias assessed (RoB 2), Lack of individual patient-level data precluded detailed subclassification of the Asian group
- Random-effects
- PRISMA
- Risk of bias assessed (RoB 2)
- Lack of individual patient-level data precluded detailed subclassification of the Asian group
Pooled result
As reported in the abstract
GLP-1 RA-associated MACE HR
Asian
0.69
HR · 95% CI 0.58–0.83
White
0.85
HR · 95% CI 0.79–0.91
P for interaction = 0.045
Further pooled results
| Outcome | Asian | White |
|---|---|---|
| Absolute MACE risk reduction | 2.9% (95% CI 1.5–4.2) | 1.4% (CI 0.9–1.9) |
Original publication
Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity. Diabetes Care. Published 20 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →